What is delayed graft function?

Jun 2, 2024 ... Both eculizumab and efgartigimod provide more treatment benefits to patients with generalized myasthenia gravis compared with conventional immunosuppressive ... Alexion Pharmaceuticals, Inc. SOLIRIS. Prescribing information. Alexion Pharmaceuticals, Inc. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin ... SOLIRIS may lower the ability of your immune system to fight infections. • SOLIRIS increases your chance of getting serious meningococcal infections caused by ... Eculizumab inhibits complement activation and EC damage and improves renal function. ... Eculizumab? What pathophysiological model apply to secondary HUS ... Feb 7, 2024 ... Eculizumab is efficacious in acetylcholine receptor antibody (AChR-Ab)-positive refractory generalized myasthenia gravis (gMG). Apr 6, 2025 ... Eculizumab, a humanized anti-C5 monoclonal antibody, has been the standard of care for treating aHUS, and has been shown to be effective in ... SOLIRIS is a prescription medicine used to treat: • adults and children with a disease called atypical Hemolytic Uremic Syndrome (aHUS). SOLIRIS is not for use ... Soliris 300 mg concentrate for solution for infusion. Active Ingredient: eculizumab. Company: Alexion Pharma UK Ltd. See contact details. Mar 10, 2025 ... FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children ... This landmark ... Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ...